Upgrade to SI Premium - Free Trial

BioMarin's (BMRN) Pegvaliase Likely to Receive FDA Approval Amid Recent Mixed Data - Wedbush

March 22, 2016 6:32 AM
Wedbush reaffirms BioMarin Pharmaceuticals (Nasdaq: BMRN) at Neutral with a price target of $108 after the company reported that the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA

Next Articles